Literature DB >> 22238410

Muscle phosphorylase kinase deficiency: a neutral metabolic variant or a disease?

N Preisler1, M C Orngreen, A Echaniz-Laguna, P Laforet, E Lonsdorfer-Wolf, S Doutreleau, B Geny, H O Akman, S Dimauro, J Vissing.   

Abstract

OBJECTIVE: To examine metabolism during exercise in 2 patients with muscle phosphorylase kinase (PHK) deficiency and to further define the phenotype of this rare glycogen storage disease (GSD).
METHODS: Patient 1 (39 years old) had mild exercise-induced forearm pain, and EMG showed a myopathic pattern. Patient 2 (69 years old) had raised levels of creatine kinase (CK) for more than 6 months after statin treatment. Both patients had increased glycogen levels in muscle and PHK activity <11% of normal. Two novel pathogenic nonsense mutations were found in the PHKA1 gene. The metabolic response to anaerobic forearm exercise and aerobic cycle exercise was studied in the patients and 5 healthy subjects.
RESULTS: Ischemic exercise showed a normal 5-fold increase in plasma lactate (peak 5.7 and 6.9 mmol/L) but an exaggerated 5-fold increase in ammonia (peak 197 and 171 μmol/L; control peak range 60-113 μmol/L). An incremental exercise test to exhaustion revealed a blunted lactate response (5.4 and 4.8 mmol/L) vs that for control subjects (9.6 mmol/L; range 7.1-14.3 mmol/L). Fat and carbohydrate oxidation rates at 70% of peak oxygen consumption were normal. None of the patients developed a second wind phenomenon or improved their work capacity with an IV glucose infusion.
CONCLUSION: Our findings demonstrate that muscle PHK deficiency may present as an almost asymptomatic condition, despite a mild impairment of muscle glycogenolysis, raised CK levels, and glycogen accumulation in muscle. The relative preservation of glycogenolysis is probably explained by an alternative activation of myophosphorylase by AMP and P(i) at high exercise intensities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22238410     DOI: 10.1212/WNL.0b013e31824365f9

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  Myopathies Related to Glycogen Metabolism Disorders.

Authors:  Mark A Tarnopolsky
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 2.  Metabolic Myoglobinuria.

Authors:  Emanuele Barca; Valentina Emmanuele; Salvatore Billi DiMauro
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

Review 3.  Glycogen metabolism and glycogen storage disorders.

Authors:  Shibani Kanungo; Kimberly Wells; Taylor Tribett; Areeg El-Gharbawy
Journal:  Ann Transl Med       Date:  2018-12

Review 4.  Neuromuscular disorders of glycogen metabolism.

Authors:  Elisabetta Gazzerro; Antoni L Andreu; Claudio Bruno
Journal:  Curr Neurol Neurosci Rep       Date:  2013-03       Impact factor: 5.081

Review 5.  Regulation of glycogen breakdown and its consequences for skeletal muscle function after training.

Authors:  Abram Katz; Håkan Westerblad
Journal:  Mamm Genome       Date:  2014-04-29       Impact factor: 2.957

Review 6.  Treatment Opportunities in Patients With Metabolic Myopathies.

Authors:  Mette Cathrine Ørngreen; John Vissing
Journal:  Curr Treat Options Neurol       Date:  2017-09-21       Impact factor: 3.598

7.  Diagnostic evaluation of rhabdomyolysis.

Authors:  Jessica R Nance; Andrew L Mammen
Journal:  Muscle Nerve       Date:  2015-03-14       Impact factor: 3.217

Review 8.  Exercise in muscle glycogen storage diseases.

Authors:  Nicolai Preisler; Ronald G Haller; John Vissing
Journal:  J Inherit Metab Dis       Date:  2014-10-18       Impact factor: 4.982

9.  Novel PHKA1 mutation in glycogen storage disease type IXD with typical myotonic discharges.

Authors:  Cong-Cong Wang; Bing Yang; Ying Liu; Xiao-Li Li; Bin Liu; Rui-Sheng Duan
Journal:  CNS Neurosci Ther       Date:  2022-08-11       Impact factor: 7.035

Review 10.  Rhabdomyolysis: a genetic perspective.

Authors:  Renata Siciliani Scalco; Alice R Gardiner; Robert Ds Pitceathly; Edmar Zanoteli; Jefferson Becker; Janice L Holton; Henry Houlden; Heinz Jungbluth; Ros Quinlivan
Journal:  Orphanet J Rare Dis       Date:  2015-05-02       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.